Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies

Page 10 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.

• AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™TerminatedNCT00058747Phase 2
• Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00055874Phase 3
• Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00053248Phase 1/2
• Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00053144Phase 1
• Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell TransplantTerminatedNCT00052598Phase 1/2
• Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationCompletedNCT00052520Phase 1/2
• High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00050531Phase 3
• Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
• Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
• Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2
• Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedNCT00047502Phase 1
• Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00045422Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042016Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042003Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00041990Phase 2
• Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated LymphocytesWithdrawnNCT00038870Not applicable
• CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationTerminatedNCT00038818Not applicable
• Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)CompletedNCT00038597Phase 2
• PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or IntronTerminatedNCT00037882Phase 2
• Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)CompletedNCT00034684Phase 1/2
• Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
• Vaccine Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030303Phase 1
• Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT00028847Phase 1/2
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00027924Phase 2
• Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic PhaseCompletedNCT00027144Phase 1
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous LeukemiaStatus unknownNCT00025402Phase 3
• Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
• Bortezomib in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00023881Phase 2
• STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00015860Phase 1/2
• STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00015834Phase 1/2
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Troxacitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00012259Phase 2
• Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid LeukemiaCompletedNCT00011934Phase 2
• STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast CrisisCompletedNCT00006475Phase 2
• Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00006364Phase 2
• STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaCompletedNCT00006343Phase 3
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
• Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00006091Phase 2
• STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaCompletedNCT00006053Phase 2
• STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00006052Phase 2
• Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous LeukemiaTerminatedNCT00005986Phase 2
• Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00005948Phase 2
• Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00005799Not applicable
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous LeukemiaCompletedNCT00005618Phase 2
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaTerminatedNCT00004933Phase 3
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute LeukemiaCompletedNCT00004905Phase 2
• Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid LeukemiaWithdrawnNCT00004878Phase 2
• Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid MetaplasiaCompletedNCT00004181Phase 2
• Vaccine Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00004052Phase 2
• Chemotherapy in Treating Patients Who Have Hematologic CancerCompletedNCT00004047Phase 1
• R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00004009Phase 1
• 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00003997Phase 1
• Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00003727Phase 2
• Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT00003694Phase 2
• Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT00003693Phase 1
• Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaTerminatedNCT00003561Phase 2
• Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00003239Phase 2
• Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00003230Phase 1/2
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid LeukemiaCompletedNCT00003145Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00002890Phase 1
• Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaStatus unknownNCT00002869Phase 3
• Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCompletedNCT00002833Phase 2
• Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT00002832Phase 1/2
• Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002800Phase 2
• Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid LeukemiaCompletedNCT00002789Phase 3
• Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00002778Phase 2
• Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous LeukemiaStatus unknownNCT00002771Phase 3
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous LeukemiaWithdrawnNCT00002761Phase 1/2
• Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute LeukemiaCompletedNCT00002693Phase 1
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002674Phase 2
• Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002598Phase 2
• Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002592Phase 2
• Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002574Phase 2
• The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic MalignanciesCompletedNCT00001432
• Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous LeukemiaCompletedNCT00001144Phase 2

← Leukemia, Myelogenous, Chronic, BCR-ABL Positive overview